Treatment Clinical Trials for Multiple Myeloma
Clinical trials are research studies that involve people. The clinical trials on this list are for multiple myeloma treatment. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Rituximab and Ibritumomab Tiuxetan in Treating Patients With Stage II-III Multiple Myeloma
This phase II trial is studying the side effects and how well giving rituximab and yttrium Y 90 ibritumomab tiuxetan together works in combination with high dose chemotherapy and autologous stem cell transplant in treating patients with stage II-III multiple myeloma. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Radiolabeled monoclonal antibodies, such as yttrium Y 90 ibritumomab tiuxetan, can find tumor cells and carry tumor-killing substances to them without harming normal cells. Giving rituximab together with indium In 111 ibritumomab tiuxetan and yttrium Y 90 ibritumomab tiuxetan may be an effective treatment for multiple myeloma.
Location: Tufts Medical Center, Boston, Massachusetts
Atezolizumab in Treating Participants with Asymptomatic Myeloma
This phase I trial studies how well atezolizumab works in treating participants with asymptomatic myeloma. Monoclonal antibodies, such as atezolizumab, may interfere with the ability of cancer cells to grow and spread.
Location: See Clinical Trials.gov